secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001140361-24-036279
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed Q2 2024 revenue $90.3M (+17% YoY); net loss $300.6M; guides FY $340-360M
-------------------------------------------------------------------------------

- ARIKAYCE global revenue $90.3M in Q2 2024, up 17% YoY; U.S. $63.8M, Japan $21.1M, Europe $5.4M.
- Net loss $300.6M ($1.94/sh) vs $244.8M loss ($1.78/sh) in Q2 2023; includes $103.7M non-cash fair value charge.
- Reiterated FY2024 ARIKAYCE revenue guidance $340M-$360M, representing ~15% YoY growth at midpoint.
- Completed public offering of 14.5M shares; net proceeds $713.2M. Redeemed $225M convertible notes due 2025.
- Plan to file NDA for brensocatib in bronchiectasis in Q4 2024; Phase 3 ASPEN met primary endpoint with statistical significance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036124036279/0001140361-24-036279-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036124036279/ef20033779_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-036279

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer